Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY “I Don’t Use Biosimilars,” Says Ex-Chief of Japan College of Rheumatology
April 5, 2017
-
REGULATORY MHLW Sets Up Office for Startup Support, Starts Receiving Applications for Consultations
April 4, 2017
-
BUSINESS EA Pharma Eager to Roll Out Several New Drugs in Next Couple of Years
April 3, 2017
-
TRENDS Mitsubishi Tanabe’s Exit Shows Research-Driven Makers’ Generic Biz at Crossroads
March 31, 2017
-
BUSINESS Tokyo Prosecutors File Appeal in Diovan Case
March 30, 2017
-
BUSINESS Mitsubishi Tanabe to Pull Plug on Generics, Transfer Biz to Nipro in October
March 29, 2017
-
ORGANIZATION Wholesalers to Address Product Return Issue after Fake Harvoni Case: JPWA Chair
March 28, 2017
-
ORGANIZATION Vaccine Association to Standardize Presentation of Expiration Dates above Inspection Dates on Outer Packaging
March 27, 2017
-
BUSINESS Wholesale Dealer President Deeply Sorry for Letting Fake Harvoni into Supply Chain
March 24, 2017
-
TRENDS As Takeda’s R&D Rejig Progresses, Biotech JV Launch Sets Direction for Its Japan Regime
March 23, 2017
-
BUSINESS Japan Begins Using PD-L1 Expression Biomarker for Immune Checkpoint Inhibitors, but Challenges Linger
March 22, 2017
-
ORGANIZATION Study Group Presents Proposal for Future Vision for Kampo Medicines
March 21, 2017
-
BUSINESS Court Finds Data Manipulation, but Not False Advertising: Diovan Case
March 17, 2017
-
BUSINESS Novartis, Ex-Employee Found Not Guilty in Diovan Case
March 16, 2017
-
REGULATORY Chuikyo Begins Debate on Gap-Year Price Revisions; Industry Frets Advance Announcement of Discrepancy Threshold
March 16, 2017
-
BUSINESS Takeda Biotech JV to Focus on 8 Projects for Now, Eyes IPO: CEO Okumura
March 15, 2017
-
REGULATORY Celgene Faces Biz Improvement Order over Delays in Side Effect Reporting
March 15, 2017
-
BUSINESS INCJ, Takeda, Medipal to Form Biotech Venture
March 14, 2017
-
BUSINESS 1st Line Use, Administration Interval Will Be Key Differentiator for Keytruda: MSD Japan Chief
March 14, 2017
-
REGULATORY Tokyo, Osaka Govts Issue Biz Improvement Order to Dealers over Fake Harvoni
March 14, 2017
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…